Gelonghui, January 30 | Ruikang Pharmaceutical (002589.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 20 million yuan to 30 million yuan, turning a year-on-year loss into a profit; net profit loss after deducting non-recurring profit and loss was 130 million yuan to 190 million yuan, a decrease of 79.52%-85.98% compared to the same period last year; basic earnings per share were 0.0133 yuan/share to 1990.00.0/share.
The main reason why the 2023 results turned losses into profits compared to the same period of the previous year: the disposal of subsidiaries affected investment income and fair value change income. The company reached a settlement with some of the subsidiaries that had lost control in the previous period, and minority shareholders of the holding subsidiary bought back the shares. At the same time, the company disposed of some of its subsidiaries unrelated to its main business. The impact of dealing with the above situation on the investment income and fair value change income of listed companies by dealing with the above situation is estimated to be about 200 million yuan. This portion is recognized as non-recurring profit and loss.